ScripPharma Breaks Bread With Trump And RFK Jr But Will They Butt Heads? Donald Trump’s second term as US president does not begin until 20 January but pharma executives spent much of last year wondering w
In VivoWith the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi
ScripIt has been less than three years since Atlas Venture closed its thirteenth venture capital fund and one thing is unchanged with its fourteenth – the size of the fund. Atlas announced on 5 December th
In VivoIn late October 2024, the first patient in a trial of Ariceum’s radioligand therapy (RLT) for glioblastoma, an aggressive brain cancer, showed 50% tumor shrinkage after just four to six weeks of tre